<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>2016 WHO myelodysplastic syndrome subtypes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">2016 WHO myelodysplastic syndrome subtypes</h1>
<div class="graphic"><div class="figure"><div class="ttl">2016 WHO myelodysplastic syndrome subtypes</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Name</td> <td class="subtitle1">Dysplastic lineages</td> <td class="subtitle1">Cytopenias*</td> <td class="subtitle1">Ring sideroblasts as % of marrow erythroid elements</td> <td class="subtitle1">BM and PB blasts</td> <td class="subtitle1">Cytogenetics by conventional karyotype analysis</td> </tr> <tr class="divider_bottom"> <td><strong>MDS with single lineage dysplasia (MDS-SLD)</strong></td> <td class="centered">1</td> <td class="centered">1 or 2</td> <td>&lt;15%/&lt;5%<sup>¶</sup></td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class="divider_bottom"> <td><strong>MDS with multilineage dysplasia (MDS-MLD)</strong></td> <td class="centered">2 or 3</td> <td class="centered">1 to 3</td> <td>&lt;15%/&lt;5%<sup>¶</sup></td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr> <td colspan="6"><strong>MDS with ring sideroblasts (MDS-RS)</strong></td> </tr> <tr> <td class="indent1">MDS-RS with single lineage dysplasia (MDS-RS-SLD)</td> <td class="centered">1</td> <td class="centered">1 or 2</td> <td>≥15%/≥5%<sup>¶</sup></td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class="divider_bottom"> <td class="indent1">MDS-RS with multilineage dysplasia (MDS-RS-MLD)</td> <td class="centered">2 or 3</td> <td class="centered">1 to 3</td> <td>≥15%/≥5%<sup>¶</sup></td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class="divider_bottom"> <td><strong>MDS with isolated del(5q)</strong></td> <td class="centered">1 to 3</td> <td class="centered">1 to 2</td> <td>None or any</td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>del(5q) alone or with 1 additional abnormality except –7 or del(7q)</td> </tr> <tr> <td colspan="6"><strong>MDS with excess blasts (MDS-EB)</strong></td> </tr> <tr> <td class="indent1">MDS-EB-1</td> <td class="centered">0 to 3</td> <td class="centered">1 to 3</td> <td>None or any</td> <td>BM 5 to 9% or PB 2 to 4%,<br/> no Auer rods</td> <td>Any</td> </tr> <tr class="divider_bottom"> <td class="indent1">MDS-EB-2</td> <td class="centered">0 to 3</td> <td class="centered">1 to 3</td> <td>None or any</td> <td>BM 10 to 19% or PB 5 to 19% or Auer rods</td> <td>Any</td> </tr> <tr> <td colspan="6"><strong>MDS, unclassifiable (MDS-U)</strong></td> </tr> <tr> <td class="indent1">With 1% blood blasts</td> <td class="centered">1 to 3</td> <td class="centered">1 to 3</td> <td>None or any</td> <td>BM &lt;5%,<br/> PB = 1%,<sup>Δ</sup><br/> no Auer rods</td> <td>Any</td> </tr> <tr> <td class="indent1">With single lineage dysplasia and pancytopenia</td> <td class="centered">1</td> <td class="centered">3</td> <td>None or any</td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>Any</td> </tr> <tr class="divider_bottom"> <td class="indent1">Based on defining cytogenetic abnormality</td> <td class="centered">0</td> <td class="centered">1 to 3</td> <td>&lt;15%<sup>◊</sup></td> <td>BM &lt;5%,<br/> PB &lt;1%,<br/> no Auer rods</td> <td>MDS-defining abnormality</td> </tr> <tr> <td><strong>Refractory cytopenia of childhood</strong></td> <td class="centered">1 to 3</td> <td class="centered">1 to 3</td> <td>None</td> <td>BM &lt;5%,<br/> PB &lt;2%</td> <td>Any</td> </tr> </tbody></table></div><div class="graphic_footnotes">BM: bone marrow; PB: peripheral blood; MDS: myelodysplastic syndrome<br/>* Cytopenias defined as: hemoglobin, &lt;10 g/dL; platelet count, &lt;100 × 10<sup>9</sup>/L; and absolute neutrophil count, &lt;1.8 × 10<sup>9</sup>/L. Rarely, MDS may present with mild anemia or thrombocytopenia above these levels. Peripheral blood monocytes must be &lt;1 × 10<sup>9</sup>/L.<br/>¶ If <em>SF3B1</em> mutation is present.<br/>Δ One percent peripheral blood blasts must be recorded on at least 2 separate occasions.<br/><font class="lozenge">◊</font> Cases with ≥15% ring sideroblasts by definition have significant erythroid dysplasia, and are classified as MDS-RS-SLD.</div><div class="graphic_reference">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 110233 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
